Skip to content

Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial

Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00520338
Enrollment
80
Registered
2007-08-24
Start date
2007-08-31
Completion date
2009-12-31
Last updated
2010-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cyclooxygenase 2 Inhibitors, Postoperative Pain, Thyroidectomy

Keywords

celecoxib, postoperative pain, thyroidectomy

Brief summary

The purpose of this study is to determine whether celecoxib is effective in the treatment postoperative pain after thyroidectomy. The research hypothesis: There is a difference in postoperative morphine consumption in the first 24 hours after thyroidectomy between patients who received celecoxib or placebo.

Detailed description

Postoperative pain has been concerned in the past few years by both the anesthesiologists ans the surgeons. COX2-inhibitors have played an important roles in postoperative pain with minimal side effects. Comparison(s): There is a difference in postoperative morphine consumption in the first 24 hours after thyroidectomy between patients who received celecoxib and placebo.

Interventions

DRUGcelecoxib

1. placebo 2. celecoxib 400 mg oral single dose

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient ASA physical status I-III. 2. Scheduled for an elective thyroidectomy. 3. Body weight \> or = 40kg 4. Can operate a patient-controlled analgesia (PCA) device.

Exclusion criteria

1. History of asthma, acute rhinitis, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other NSAIDs. 2. Known hypersensitivity to morphine or sulfonamides. 3. History of hepatic dysfunction. 4. Creatinine clearance \< 30ml/min. 5. History of bleeding tendency. 6. History of gastrointestinal bleeding or active peptic ulcer. 7. Known case of inflammatory bowel disease. 8. Patient with severe heart failure.

Design outcomes

Primary

MeasureTime frame
The patients' total amount of morphine requirement in the first 24 hour.24 hour

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026